GCP
MRTX

GSA Capital Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

GSA Capital Partners’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,083
Closed -$336K – 1863
2021
Q2 		$336K Buy
+2,083
New +$334K 0.04% 875
2018
Q2 		– Sell
-16,544
Closed -$508K – 1995
2018
Q1 		$508K Buy
+16,544
New +$459K 0.03% 1053
2016
Q4 		– Sell
-34,999
Closed -$231K – 2014
2016
Q3 		$231K Buy
+34,999
New +$186K 0.01% 1531

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

GSA Capital Partners's MRTX Position: Q3 2021 in Review

GSA Capital Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2021, closing a stake of 2,083 shares — an estimated $336K sold.

GSA Capital Partners first reported a position in MRTX in Q3 2016 and held it in 3 quarters. The position peaked at $508K in Q1 2018. 238 funds tracked by Wall St. Rank hold MRTX as of Q3 2021.

  • GSA Capital Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • GSA Capital Partners sold 2,083 Mirati Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $336K.
  • GSA Capital Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2016 and held it in 3 quarters.
  • GSA Capital Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $508K in Q1 2018.
  • 238 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2021.

Based on GSA Capital Partners's 13F filing for Q3 2021, filed 12 Nov 2021.